Volume 19, Issue 6, Pages (June 2016)

Slides:



Advertisements
Similar presentations
“Neutralizing Antibodies Derived from the B Cells of 1918 Influenza Pandemic Survivors” (Yu et. al) Daniel Greenberg.
Advertisements

The Quest for a Universal Flu Vaccine: Headless HA 2.0
Figure 1. Antibody responses against homologous 2013 H7 virus in H7N9-infected patients. A, Serum samples from H7N9-infected patients were collected at.
In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections  Chasity D. Andrews,
An Insertion Mutation That Distorts Antibody Binding Site Architecture Enhances Function of a Human Antibody Jens C. Krause, Damian C. Ekiert, Terrence.
Volume 10, Issue 4, Pages (April 1999)
Influenza Vaccines: Challenges and Solutions
Volume 158, Issue 6, Pages (September 2014)
Volume 165, Issue 7, Pages (June 2016)
Volume 17, Issue 3, Pages (March 2015)
Volume 14, Issue 1, Pages (July 2013)
Volume 12, Issue 4, Pages (October 2012)
Volume 18, Issue 3, Pages (September 2015)
Volume 6, Issue 5, Pages (November 2009)
Volume 16, Issue 1, Pages (July 2014)
Volume 23, Issue 1, Pages (July 2005)
Volume 22, Issue 7, Pages (July 2014)
Volume 22, Issue 7, Pages (July 2014)
Durbaka V.R Prasad, Sabrina Richards, Xoi Muoi Mai, Chen Dong  Immunity 
Volume 22, Issue 2, Pages (August 2017)
Glycan Receptor Binding of the Influenza A Virus H7N9 Hemagglutinin
Luisa De Sordi, Varun Khanna, Laurent Debarbieux  Cell Host & Microbe 
Volume 167, Issue 3, Pages e9 (October 2016)
Volume 6, Issue 4, Pages (October 2009)
Volume 1, Issue 1, Pages (March 2007)
Fig. 6. Epitope mapping of C12G6.
Volume 4, Issue 3, Pages (September 2008)
Volume 14, Issue 4, Pages (October 2013)
Volume 16, Issue 3, Pages (September 2014)
Figure 3. MAb 19H9 displays broad cross-reactivity with IAV strains of different subtypes. (A), Amino acid sequence ... Figure 3. MAb 19H9 displays broad.
Volume 20, Issue 3, Pages (September 2016)
Volume 1, Issue 2, Pages (April 2007)
Volume 19, Issue 2, Pages (February 2016)
Volume 13, Issue 12, Pages (December 2015)
Volume 19, Issue 5, Pages (May 2016)
Adam S. Dingens, Hugh K. Haddox, Julie Overbaugh, Jesse D. Bloom 
Volume 29, Issue 2, Pages (August 2008)
Volume 13, Issue 4, Pages (April 2013)
In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections  Chasity D. Andrews,
Volume 15, Issue 5, Pages (May 2014)
Volume 22, Issue 2, Pages (August 2017)
Fig. 1. In vitro binding and neutralization activities of C12G6.
Volume 10, Issue 3, Pages (September 2011)
Volume 13, Issue 3, Pages (March 2013)
Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus
Volume 21, Issue 6, Pages e8 (June 2017)
Ebolavirus’s Foibles Cell
Volume 25, Issue 5, Pages (October 2018)
Volume 11, Issue 9, Pages (June 2015)
Volume 29, Issue 6, Pages (June 2016)
Volume 14, Issue 2, Pages (August 2008)
Volume 19, Issue 2, Pages (April 2017)
Volume 9, Issue 1, Pages (January 2011)
A Stable Prefusion Intermediate of the Alphavirus Fusion Protein Reveals Critical Features of Class II Membrane Fusion  Claudia Sánchez-San Martín, Hernando.
Volume 8, Issue 2, Pages (August 2010)
Volume 21, Issue 1, Pages (January 2017)
Volume 24, Issue 6, Pages (June 2016)
Volume 46, Issue 4, Pages (April 2017)
Volume 24, Issue 7, Pages e5 (August 2018)
Volume 24, Issue 7, Pages (August 2018)
Volume 12, Issue 3, Pages (September 2012)
Volume 153, Issue 7, Pages (June 2013)
Volume 10, Issue 2, Pages (August 2011)
HIV Broadly Neutralizing Antibodies: Taking Good Care Of The 98%
Volume 24, Issue 1, Pages (January 2016)
Broadening Horizons: New Antibodies Against Influenza
Atsushi Yamanaka, Eiji Konishi
Functional characterization of multidonor class antibodies.
Volume 115, Issue 4, Pages (October 1998)
How the T Cell Repertoire Becomes Peptide and MHC Specific
Presentation transcript:

Volume 19, Issue 6, Pages 800-813 (June 2016) Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection  Carole J. Henry Dunand, Paul E. Leon, Min Huang, Angela Choi, Veronika Chromikova, Irvin Y. Ho, Gene S. Tan, John Cruz, Ariana Hirsh, Nai-Ying Zheng, Caitlin E. Mullarkey, Francis A. Ennis, Masanori Terajima, John J. Treanor, David J. Topham, Kanta Subbarao, Peter Palese, Florian Krammer, Patrick C. Wilson  Cell Host & Microbe  Volume 19, Issue 6, Pages 800-813 (June 2016) DOI: 10.1016/j.chom.2016.05.014 Copyright © 2016 Elsevier Inc. Terms and Conditions

Cell Host & Microbe 2016 19, 800-813DOI: (10.1016/j.chom.2016.05.014) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 1 Characterization of Human H7-Reactive Antibodies (A) Human monoclonal antibodies (mAbs) were cloned from plasmablasts isolated at day 7 after the inactivated H7N9 vaccine. (B) Twenty H7-reactive mAbs were screened for HAI, neutralization, and cross-reactivity to diverse influenza A HAs (group 1 and 2). (C) Binding to recombinant HA proteins was tested by ELISA. Representative minimum positive concentrations (μg/ml) from three independent experiments are plotted as a heatmap. The different HAs were clustered by amino acid sequence phylogeny, and multiple alignments were performed using the CLUSTALW algorithm. A rooted tree was constructed using the neighbor-joining method and was visualized using FigTree v1.4.0 software. mAbs are grouped by individuals (22, 07, 24, and 41), and HAI+ Neut+, HAI− Neut+ and HAI− Neut− categories are mentioned. Affinity measurements (KD) determined by biolayer interferometry for A/Shanghai/1/2013 (H7N9) HA are displayed in purple. See also Table S1 and Figure S1. Cell Host & Microbe 2016 19, 800-813DOI: (10.1016/j.chom.2016.05.014) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 2 Human H7-Reactive Antibodies Exhibit Various In Vitro Functional Characteristics (A–D) Minimum positive concentrations in μg/ml (mean ± SEM) are reported for HAI; IC50 in μg/ml (mean ± SEM) are reported for neutralization. Experiments were done in duplicate three times. (A) HAI and neutralization assays were performed with A/Shanghai/1/2013 (H7N9) virus. (B) Neutralization of various group 1 and 2 viruses based on previous ELISA results; n.d., not determined. In color are reported previous neutralization results from (A) with H7N9. (C) HAI was performed with various H7 viruses from the Eurasian (H7N7) and North American (H7N3 and H7N1) lineages. Only the HAI+ Neut+ mAbs were tested. (D) HAI was performed with wild-type A/Anhui/1/2013 (H7N9) virus and with an escape mutant virus that displays mutations in the H7 HA antigenic site A (R149G). Only the HAI+ Neut+ mAbs were tested. No HAI activity was observed for 07-4D05 with the escape mutant (R149G). See also Figure S1. Cell Host & Microbe 2016 19, 800-813DOI: (10.1016/j.chom.2016.05.014) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 3 Human H7-Reactive Antibodies Confer Protection In Vivo 6- to 8-week-old female BALB/c mice were injected with 5, 1, or 0.3 mg/kg of each mAb and then infected with 7.5 LD50 of A/Shanghai/1/2013 (H7N9) virus. Values represent mean ± SEM (n = 5 mice per group). (A–J) Percent of initial weight and percent survival are plotted for each mAb: (A) 07-5D03, (B) 07-5F01, (C) 07-5G01, (D) 07-4B03, (E) 22-3E05, (F) 07-5B05, (G) 41-5E04, (H), 41-5D06, (I) 07-5E01, and (J) 24-4C01. Mice that received an H3-reactive but not H7-reactive mAb (011-2C01) died at day 6 after the challenge. The same control group of mice was used for all panels. See also Figure S2. Cell Host & Microbe 2016 19, 800-813DOI: (10.1016/j.chom.2016.05.014) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 4 Human H7-Neutralizing Antibodies Bind to Various Epitopes on the HA Stalk and Head Domains Escape mutant variants with A/Shanghai/1/2013 (H7N9) virus were generated for the neutralizing mAbs. Sequences for each mutant were compared to the wild-type virus, and unique mutations were reported. (A) Critical residues for binding of Neut+ mAbs are reported. Nomenclature for substitutions follows the rule of original residue, position of the amino acid, new residue (H3 numbering). (B and C) Modeling of A/Shanghai/1/2013 H7 HA was done using PyMOL (PDB: 4LN3). HAI+ Neut+ critical residues are shown in red and HAI− Neut+ residues are shown in yellow. The Arg65 residue (HAI+ and HAI−) is shown in orange. See also Figure S3. Cell Host & Microbe 2016 19, 800-813DOI: (10.1016/j.chom.2016.05.014) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 5 Neutralizing and Non-Neutralizing H7-Reactive Antibodies Bind to Different Epitopes on Hemagglutinin (A) Biotinylated mAbs 41-5E04 (HAI− Neut+) and 41-5D06 (HAI− Neut−) were tested for binding to A/Shanghai/1/2013 HA by ELISA with or without the presence of a competitor mAb. The experiment was done in duplicate three times. The percentage of competition between the 41-5E04 and 41-5D06 (in red) and the non-neutralizing mAbs or CR9114 is shown. Absorbance value of each mAb against itself is scored at 100% inhibition, and comparison of different mAbs was done as a percentage of this 100% inhibition. (B) Purified virus preparations were treated with various pH-buffered solutions (from pH 7.0 to 4.4), and binding (at pH 7.4) to HA was measured by ELISA. Antibody binding was tested in duplicate and in two independent experiments. Values represented here are mean ± SEM. See also Figure S4. Cell Host & Microbe 2016 19, 800-813DOI: (10.1016/j.chom.2016.05.014) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 6 Fc-FcγR Interactions Are Important for In Vivo Protection by Non-Neutralizing Antibodies The HAI− Neut− mAbs and one HAI+ Neut+ antibody were cloned in an IgG2a mouse construct with or without the D265A mutation (DiLillo et al., 2014). (A) Binding of the mouse mAbs to A/Shanghai/1/2013 (H7N9) viruses by ELISA. Values represent mean ± SEM from triplicate wells. (B) In vitro MN with A/Shanghai/1/2013 (H7N9) viruses. Values represent mean from duplicate wells and shown here is one representative of two independent experiments. (C) 6- to 8-week-old female BALB/c mice were injected with one dose of each mouse mAb and then infected with a sublethal dose of A/Shanghai/1/2013 (H7N9) virus. Values represent mean ± SEM (n = 4 mice per group). Percent of initial weight are plotted for each mAb: 3 mg/kg for 07-5E01, 4 mg/kg for 41-5D06, 3 mg/kg for 24-4C01, and 4 mg/kg 07-5G01. Mice that received an irrelevant H6-reactive IgG2a mAb were used as a control. The same control group of mice was used for all panels. See also Figures S5 and S6. Cell Host & Microbe 2016 19, 800-813DOI: (10.1016/j.chom.2016.05.014) Copyright © 2016 Elsevier Inc. Terms and Conditions